A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial.
Authors
Cook, GWilliams, C
Cairns, D
Hockaday, A
Cavanagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Pratt, G
Chown, S
Heartin, E
O'Connor, S
Ashcroft, A
Brown, J
Morris, T
Affiliation
Leeds Institute of Cancer & Pathology, University of LeedsIssue Date
2016